Ibogaine vs. Suboxone and Methadone Maintenance in Long-Term Recovery

Key Takeaways

• Buprenorphine with naloxone and methadone are maintenance medications. They work by keeping mu-opioid receptors occupied so withdrawal and cravings stay controlled, and both have a large evidence base behind them.
• Ibogaine is being investigated as a different kind of intervention, one aimed at helping people move away from opioid dependence rather than manage it over time.
• A person on buprenorphine or methadone cannot move directly into ibogaine treatment. Those medications occupy the opioid system too thoroughly, which is why a supervised transition to a short-acting opioid comes first.
• Withdrawal from buprenorphine and methadone tends to run longer than withdrawal from heroin or fentanyl, and some symptoms can linger for weeks or months after the acute phase ends.
• Research on ibogaine for opioid use disorder is still developing. No randomized controlled trial has been completed in this population, and the medication carries real cardiac risk that requires screening.
• Maintenance is a legitimate long-term choice for many people. The useful question is not which treatment wins, but which approach fits a specific person’s medical situation and goals.

When navigating treatment options for opioid use disorder, individuals often encounter two distinct medical philosophies: long-term maintenance and transition-oriented interventions. While established maintenance medications like buprenorphine and methadone provide stability by managing cravings and withdrawal over time, emerging alternatives like ibogaine aim to help individuals move away from opioid dependence entirely. Choosing the right path requires understanding how these treatments interact, the unique timelines of physical withdrawal, and the current scientific evidence surrounding their safety and efficacy. The following guide outlines how these approaches compare, as well as what factors dictate a safe, effective recovery strategy.

What Are Suboxone and Methadone?

Opioid addiction rarely responds to one standard protocol. What helps a person who has used heroin for six months may not fit someone who has been on a methadone program for a decade, and treatment options have to account for that. Before comparing ibogaine to maintenance medication, it helps to be precise about what these medications are and what they were designed to do.

Understanding Suboxone (Buprenorphine and Naloxone)

Suboxone is a brand name for a medication containing two active ingredients, buprenorphine and naloxone. Buprenorphine is a partial opioid agonist. It binds to the brain’s mu-opioid receptors and activates them, but to a lesser degree than full agonists like heroin or fentanyl. That partial activation is enough to hold withdrawal symptoms and cravings at bay without producing the intensity of a full agonist.

Buprenorphine also binds very tightly. Its affinity for the mu-opioid receptor is high enough that it displaces other opioids and blunts their effects, which is part of why it works so well as a maintenance medication and part of why transitioning off it is complicated. According to guidance published by the Substance Abuse and Mental Health Services Administration, that same tight binding is what causes precipitated withdrawal when buprenorphine is introduced too soon after a full agonist.

Naloxone is the second ingredient. It is a pure opioid antagonist included as a misuse deterrent rather than as a therapeutic agent. Taken sublingually as directed, its bioavailability is under 10%, and its effect is clinically negligible. If the tablet or film is dissolved and injected, naloxone becomes bioavailable, blocks receptor activation, and precipitates withdrawal. That feature is the deterrent. It discourages injection and insufflation (breathing or blowing a gas into the respiratory tract) without interfering with the medication when it is used correctly.

Buprenorphine with naloxone can be an important treatment option for opioid use disorder. It reduces overdose death, keeps people engaged in care, and can be prescribed in an ordinary medical office rather than a specialty clinic, which removed a significant access barrier when it was introduced.

Understanding Methadone

Methadone is a long-acting full opioid agonist used in the treatment of opioid use disorder. It occupies mu-opioid receptors steadily over a long duration, which prevents withdrawal and reduces cravings without the peaks and crashes of short-acting opioids. Like buprenorphine, it has decades of research behind it showing reductions in overdose death and in the behaviors that transmit HIV and hepatitis C.

In the United States, methadone for opioid use disorder is dispensed through certified opioid treatment programs rather than retail pharmacies. Patients typically begin by attending the clinic daily for observed dosing, and take-home privileges are extended as treatment progresses. The rules governing that process changed meaningfully in 2024, when a federal final rule removed the eight restrictive take-home criteria and allowed take-home doses from treatment entry based on the treating provider’s clinical judgment. However, programs still vary widely in how they apply that discretion, so a patient’s day-to-day experience depends heavily on which clinic they attend.

What Is Ibogaine?

Ibogaine is a psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, a plant-based medicine used in West Central African traditional practice long before Western researchers examined it for substance use disorders. It has been studied for opioid, cocaine, and alcohol dependence, and it works nothing like a maintenance medication.

How Ibogaine Differs From Opioid Maintenance Medication

Maintenance medications keep opioid receptors occupied daily. Ibogaine, on the other hand, is administered as a single supervised dose in a medical setting, and the goal is not to occupy receptors over time. Published scoping reviews describe ibogaine as acting across several systems at once, modulating nicotinic, opioid, glutamatergic, and monoaminergic signaling while influencing growth factors that help nerve cells form new connections. Researchers have proposed that this opens a period of heightened neuroplasticity, meaning the brain becomes more able than usual to rewire the circuits that drive compulsive use. That window is sometimes described as a reset.

Keep in mind that those mechanisms are proposals rather than settled facts, and we think it matters to say so plainly. Ibogaine is also metabolized into noribogaine, an active metabolite that clears slowly and varies considerably from person to person depending on CYP2D6 (an enzyme found in the liver) activity. That variability, along with other medical considerations, is why dosing has to be individualized rather than standardized.

What the Research Currently Shows

The most consistent finding across the ibogaine literature is rapid reduction of opioid withdrawal symptoms after treatment. In particular, a 191-patient open-label series conducted at an inpatient facility in St. Kitts, West Indies, recorded objective withdrawal scores dropping from a range of 3 to 13 before dosing down to 0 or 2 within roughly 36 hours.

What the field does not have, however, is randomized evidence. A 2026 scoping review in Molecules confirmed that no randomized controlled trials (RCTs) exist for ibogaine in treating opioid use disorder. Instead, current human efficacy data rely entirely on open-label observational studies, retrospective analyses, and case reports. Furthermore, a 2026 review in the Journal of Psychopharmacology identified only three randomized trials across all studied indications. One of these trials administered noribogaine to 27 opioid-dependent patients, noting a dose-dependent prolongation of the heart rate-corrected QT interval; however, the accompanying reductions in withdrawal symptoms were not statistically significant.

Anyone considering this treatment deserves that context up front rather than buried in a disclaimer. Ibogaine is not a cure, and it is not approved by the Food and Drug Administration for opioid use disorder in the United States, where it remains a controlled substance. With these restrictions, treatment is only available in countries where it is legal or unregulated, which includes Mexico. However, despite this red tape, the federal government has been reviewing ibogaine’s potential for mental health conditions and accelerating research, so the regulatory landscape is worth checking as it evolves rather than assuming.

The Fundamental Difference Between These Approaches

Suboxone and ibogaine are treatment methods with intrinsic differences that shape how an addiction is managed, and so knowing the distinctions between the two is important for deciding the best option for care plans tailored to each situation and each individual.

Maintenance Compared With Discontinuation

The distinction that matters most here is one of intent. Buprenorphine and methadone manage opioid use disorder through ongoing maintenance, and they do it well. In comparison, ibogaine is being investigated as an intervention meant to help a person move away from opioid dependence entirely.

When discussing buprenorphine and methadone, it would be easy to reduce that intent to a slogan about replacing one addiction with another, and we are not going to do that. Prescribed maintenance treatment is clinically distinct from illicit opioid use even though both act on the same receptors. The National Institute on Drug Abuse is explicit that when taken as prescribed, methadone and buprenorphine prevent cravings and withdrawal without producing the intense pleasure that drives compulsive use. A person on a stable maintenance dose is not chasing a high, is not exposed to contaminated supply, and is far less likely to die of an overdose. Those are meaningful clinical outcomes, not consolation prizes.

What is also true is that both medications keep the mu-opioid system occupied, and that has consequences for anyone who eventually wants to stop. In these circumstances, people often look to ibogaine as an alternative.

Short-Term Stabilization and Long-Term Goals

Stabilizing withdrawal and cravings is often the first thing that has to happen before anything else in a person’s life can stabilize. Housing, employment, and family relationships tend to follow from that, not precede it.

Where people diverge is what comes after stabilization. Some remain on maintenance medication indefinitely and do well. Others eventually want to taper and discontinue under medical supervision. Ibogaine treatment tends to appeal to people in that second group, particularly those who have tried tapering and found the process unmanageable. Keep in mind, though, that treatment outcomes vary, and no one should be promised otherwise.

Why People Consider Ibogaine After Years on Maintenance

Considering ibogaine after years of maintenance medication can be due to a plethora of variables, all of which are specific to the individual.

The Desire to Stop Maintenance Medication

Patients arrive at Experience Ibogaine having been on buprenorphine or methadone for anywhere from two years to twenty, and their reasons for wanting to stop are usually practical rather than ideological. Some want to travel or take a job that daily dosing makes impossible. Some are tired of a prescription schedule structuring their month. Some tried to taper, hit a wall, and went back up.

None of those reasons make maintenance a failure. A person who spent eight years stable on methadone and avoided overdose during the fentanyl era got something real out of that treatment. Wanting the next chapter to look different is a separate question from whether the last one worked.

The Practical Weight of Long-Term Maintenance

The logistics are the part patients talk about most. Buprenorphine prescriptions generally run on a monthly cycle. Methadone dosing happens at a clinic, and until take-home privileges are granted, that means showing up in person, often early in the morning, every day.

Missing a dose brings withdrawal, which makes the schedule difficult to negotiate around. Travel requires either take-home doses or a clinic at the destination willing to dose a visiting patient, and neither is guaranteed. In a 2021 qualitative study published in the Harm Reduction Journal, researchers interviewed 36 people connected to methadone treatment in New York City, including current and former patients, providers, and regulators. One patient described the arrangement in terms that have since become common among patients themselves: “it’s like liquid handcuffs.” The same study documented patients lying to employers about lateness and missing funerals because take-home requests could not be processed in time.

That phrase is patient language, not a clinical category, and it describes a logistical constraint rather than a judgment about the medication. The 2024 federal rule change was designed to loosen exactly these restrictions, but how much loosening a given patient experiences still depends on their specific program.

Why Ibogaine Treatment Is More Complicated for Maintenance Patients

Understanding the pharmacology of long-acting opioids is essential before considering ibogaine treatment. Because medications like buprenorphine and methadone firmly occupy the brain’s opioid receptors for extended periods, patients must safely transition to short-acting opioids under medical supervision before ibogaine can be effectively administered.

Receptor Occupancy Changes the Picture

Here is the part that surprises most people who call us. Ibogaine does not work on patients who are currently taking buprenorphine or methadone. This is not a policy preference or a scheduling inconvenience. It is pharmacology. Buprenorphine attaches firmly to the brain’s opioid receptors and is very slow to leave. After a dose dissolves under the tongue, it stays in the body for a long time—typically around 38 hours, but anywhere from 25 to 70 hours. In fact, it keeps blocking the receptors even after its levels in the bloodstream drop, essentially locking down the opioid system. Methadone creates a similar issue in a different way. Because it lasts so long in the body, it clears out very slowly and continues to fill the receptors long after a person takes their last dose.

When the opioid system is still occupied that thoroughly, ibogaine cannot do what it is meant to do. Attempting treatment anyway does not produce a better outcome, and it exposes the patient to the medication’s risks without the benefit.

Why Patients Cannot Switch Directly to Ibogaine

Any clinic that tells a methadone patient they can fly in next week and be dosed is either uninformed or telling that patient what they want to hear. Neither is a reason to trust them with a treatment that requires cardiac monitoring.

A patient on maintenance medication needs a period on a different opioid before ibogaine treatment becomes appropriate. How long that period runs is not a number anyone should quote from a website. It depends on the medication, the dose, how long the person has been on it, their metabolism, and the protocol of the clinic providing care.

The Transition to Short-Acting Opioids

The approach used at Experience Ibogaine and described in the published literature involves transitioning the patient from buprenorphine or methadone onto a short-acting opioid before treatment. In the St. Kitts case series, opioid-dependent patients were switched at program entry to an oral morphine sulfate solution for withdrawal control before ibogaine detoxification, which is the same principle applied on a compressed inpatient timeline.

For patients coming off long-term maintenance, that transition typically takes one to two months, and for some patients considerably longer, up to several months, before they are ready. The determination is clinical and made by a medical team reviewing that patient’s history, not by a calendar.

This transition is a serious undertaking, and it belongs under qualified medical supervision. We are merely describing how the transition works so patients understand what they are being asked to do and why, not so anyone can attempt it independently. A self-directed switch between opioid medications carries genuine risk, including overdose, and it is not something to work out alone.

The Longer Withdrawal Timeline of Buprenorphine and Methadone

Long-term opioid maintenance medications like buprenorphine and methadone cause a longer, more intense withdrawal process due to deep brain receptor adaptation, requiring a gradual, medically supervised tapering process to prevent relapse.

Why This Withdrawal Behaves Differently

Patients who have used heroin and later used maintenance medication often report that the maintenance withdrawal was harder. That observation is common enough to warrant an explanation rather than dismissal.

The mechanism is receptor adaptation. When mu-opioid receptors are stimulated artificially over a long period, the brain adapts by reducing the number of active receptors and decreasing their sensitivity to the body’s own endorphins. That is downregulation, and it takes time to reverse. The longer and more continuously the receptors have been occupied, the more adaptation there is to undo. Maintenance medications occupy receptors steadily, every day, for years, which is precisely the condition that produces the most entrenched adaptation.

Acute Withdrawal Compared With Protracted Symptoms

There is a difference between acute withdrawal and what follows it. On average, acute opioid withdrawal lasts between four and ten days, with methadone withdrawal potentially running 14 to 21 days. That is the most critical phase.

After that comes protracted withdrawal, which is defined as symptoms persisting, evolving, or appearing well past the expected timeframe for the acute phase. For opioids, that can include anxiety, depression, and sleep disturbance lasting weeks or months, along with fatigue, dysphoria, irritability, and measurable deficits in executive function.

Patients in online communities sometimes say it took a year to feel normal after stopping Methadone, highlighting the intensity of maintenance medications. Still, while users’ anecdotes are real reports of real experiences, they are not a clinical finding supported by concrete evidence. Duration varies enormously between individuals, and treating one person’s timeline as a prediction of another’s is not helpful to anyone.

Tapering Buprenorphine Safely

Stopping buprenorphine involves withdrawal as well, and the process should be individualized and medically supervised. SAMHSA’s treatment guidance is candid that no duration of therapy exists after which a patient can stop and be certain they will not return to opioid use, and that following short-term medically supervised withdrawal, patients frequently restart illicit opioid use. Gradual reductions over months are the recommended approach, with the patient retaining the authority to pause or reverse the taper.

That guidance also notes that treatment lasting under 90 days has limited effectiveness, which is worth knowing for anyone weighing whether to start maintenance at all.

Can Ibogaine Help People Transition Off Maintenance Medication?

While ibogaine has emerged as a compelling alternative for addiction recovery, navigating its potential requires a careful examination of its clinical evidence, strict safety protocols, and the distinction between a psychedelic experience and a comprehensive treatment program.

What the Evidence Actually Says

The most directly relevant study is a twelve-month observational study conducted in New Zealand and published in The American Journal of Drug and Alcohol Abuse in 2018. Of the fourteen participants who completed treatment, ten were methadone patients, which makes it unusually applicable to the question at hand.

The results were meaningful. Addiction Severity Index drug composite scores fell from 0.32 to 0.06 over twelve months, a reduction of more than 80%. Twelve of the fourteen participants achieved sustained reduced use or cessation, and 75% of those tested were urine-negative at the twelve-month mark.

One participant died during treatment, and investigation indicated the death was most probably related to a cardiac arrhythmia. The authors themselves flag the study’s limits, including a convenience sample of fourteen, participants filtered by providers, and participant drop-out over time that reduced the analyzed group numbers. This is the strongest evidence available for methadone-maintained patients, and it is a small observational study with a death in it. So, while ibogaine shows promise as a treatment option, it still lacks substantial, clinic-based evidence supporting claims.

Most of the broader ibogaine literature involves people using illicit opioids rather than patients maintained on methadone or buprenorphine, which is a distinction worth holding onto when reading success rates. Successful treatment is not a guarantee for anyone, and many factors affect positive outcomes.

Why Preparation and Screening Matter

Preparation is where outcomes are made or lost, and it starts well before anyone arrives. At Experience Ibogaine, pre-treatment screening includes a required cardiologist evaluation for every patient, complete bloodwork with a full liver function panel measuring albumin, total protein, ALP, ALT, AST, GGT, and bilirubin, along with vitamin and electrolyte levels, and a urinalysis screening for contraindicated substances.

The cardiac screening is not a formality. Ibogaine and noribogaine inhibit the hERG potassium channel that governs cardiac repolarization, and published reviews document heart rate-corrected QT interval (QTc) values exceeding 600 milliseconds in some reports, along with cases of torsades de pointes and ventricular arrhythmia. Reported fatalities have frequently involved pre-existing cardiac or hepatic disease, electrolyte disturbances, or polysubstance use, which is exactly what thorough screening is designed to identify before dosing rather than after.

Dosing is calculated individually based on weight, age, the substances used, duration of use, liver function, heart function, bloodwork, and the patient’s response to a test dose. The threshold is never pushed into dangerous territory to chase a stronger experience. Medication history and time since last opioid use also factor into the timing of the entire protocol.

Why a Psychedelic Experience Is Not the Same as Treatment

A patient can have a powerful psychedelic experience and remain exactly as dependent afterward as they were before. The experience is not the treatment. The treatment is the screening that determines whether a person can be dosed safely, the transition protocol that gets a maintenance patient ready, the monitoring during dosing, the medical management of the days that follow, and the aftercare that carries someone through the months when that window of heightened neuroplasticity is still open.

Many clinics have figured out that patients can only evaluate how they are treated, not the actual science. They take your money, give you a dose, and send you on your way. If the treatment fails under these conditions, patients usually assume ibogaine doesn’t work, rather than realizing the provider failed them. Ibogaine is a costly, risky procedure, and it is the ultimate reason you must carefully research a provider before committing to treatment.

Comparing the Long-Term Perspective

Patients tend to raise the same handful of considerations when weighing these options against one another. Here is how the three approaches compare across each one:

• Primary Approach: Buprenorphine with naloxone and methadone are both maintenance treatments with decades of clinical use behind them. Ibogaine is a treatment approach still under investigation.
• Opioid Receptor Activity: Buprenorphine partially activates mu-opioid receptors and binds to them tightly. Methadone activates them fully over a long duration. Ibogaine has a different pharmacological profile and is not used to occupy receptors over time.
• Ongoing Medication: Buprenorphine and methadone are taken daily on an ongoing basis. Ibogaine is not intended as daily maintenance, and only one full dose is considered safe within a three- to four-month period.
• Withdrawal Concerns: Discontinuing either maintenance medication produces withdrawal that can last for a long time. Ibogaine’s safety considerations center on cardiac risk rather than withdrawal.
• Treatment Setting: Buprenorphine is often prescribed in an ordinary medical office. Methadone is usually structured through a certified opioid treatment program. Ibogaine requires a specialized setting with continuous medical supervision.
• Goal: The maintenance medications aim to reduce cravings, prevent withdrawal, and lower opioid-related harm. Ibogaine aims at a potential transition away from opioid dependence altogether.
• Evidence Base: Buprenorphine and methadone are supported by extensive research. Ibogaine’s evidence base is still developing and includes no randomized trials in opioid use disorder.

Choosing the Right Treatment Path

Finding the right path for opioid recovery requires a deeply personalized plan rather than a one-size-fits-all approach. Whether long-term maintenance or an alternative treatment is the goal, an informed decision must be based on individual medical histories and personal recovery targets.

No Single Approach Fits Everyone

What makes sense for a given person depends on the severity and duration of their opioid use, what medication they are currently taking, their medical history including cardiac and liver health, what they have already tried, the support system waiting for them at home, and what they actually want their life to look like. A person with a cardiac condition and a person with 18 months of stability on buprenorphine are facing different decisions, and neither is served by a generic recommendation.

When Maintenance Is the Right Long-Term Choice

For some people, staying on medication is the right answer, and it stays the right answer. Reduced illicit opioid use and reduced overdose risk are treatment outcomes in their own right. Nothing in the clinical literature requires that everyone eventually discontinue, and NIDA notes that fewer than one in five people with opioid use disorder currently receive these medications at all, which puts the access problem in perspective.

We would rather a person stay on a medication that is working than pursue a treatment they are not ready for. That position is not at odds with what we do here; rather, it is part of our core philosophy.

When People Seek a Different Path

Other people want off maintenance and have decided that clearly. Some want a different model of recovery than daily medication, while others have researched ibogaine for years before calling. What all of them need is an honest accounting of the potential benefits, the uncertainties, the medical risks, and the cost, delivered before they commit rather than after. We want this to be your decision, which means giving you the information required to make it.

What to Consider Before Choosing Ibogaine

Ibogaine treatment offers a unique approach to dependency recovery, but it requires strict medical protocols and careful preparation to ensure safety. Navigating this complex process demands a thorough understanding of clinical screening, provider qualifications, and realistic timelines.

Medical Screening and Safety

Ibogaine carries serious medical risks, and cardiac risk is the one that has caused deaths. These risks are why comprehensive screening with cardiologist oversight is not optional. Medication interactions also have to be evaluated in advance, which includes selective serotonin reuptake inhibitors (SSRIs), since ibogaine treatment does not work with SSRIs and those medications require their own management plan. With this level of assessment required, this is not a treatment anyone should approach as a do-it-yourself detox.

How to Evaluate a Provider

Specific questions worth asking are:

• What are the medical qualifications of the staff, and is a physician present during dosing?
• What emergency equipment and protocols are in place, and how far is the nearest hospital?
• What does the screening process actually include, and is a cardiologist involved?
• How many patients has this provider treated who were coming off methadone or buprenorphine?
• What does aftercare consist of, and what happens in the weeks after a patient goes home?
• Is the treatment protocol explained in writing before payment?

A provider who guarantees results is telling you something important about themselves. Nobody can guarantee the outcome of a treatment that has not been through a randomized trial.

Cost, Timelines, and Realistic Expectations

Ibogaine treatment is a significant financial commitment, and for maintenance patients, the transition period adds months to the timeline before treatment even begins. Understanding that in advance prevents the disappointment of arriving somewhere expecting to be dosed and being told to come back in eight weeks.

Treatment length depends on what the patient is coming off. A patient dependent on fentanyl or another short-acting opioid typically stays about twelve days, and fentanyl specifically requires a flushing period using intravenous saline with ascorbic acid, taking roughly a week, before ibogaine can be administered at all. A patient who has transitioned correctly from methadone onto a short-acting opioid generally completes a program of around five days. Patients treating alcohol dependence who have already detoxed usually stay about five days, and those who need on-site detox or liver treatment stay twelve days or longer. However, the actual length of stay depends on how a patient progresses through the detox phase; treat these averages as guidelines rather than hard-and-fast rules.

How Experience Ibogaine Approaches Maintenance Patients

Experience Ibogaine provides structured, medically monitored ibogaine therapy tailored specifically for patients navigating addiction recovery and PTSD. Founded by a former patient, the clinic combines lab-sourced treatments and rigorous aftercare protocols to guide individuals through both the intense dosing session and the critical integration period that follows.

What Treatment Looks Like

Experience Ibogaine was founded by Aeden Aeharn, who overcame severe addiction through ibogaine therapy himself before building a treatment center around it. That history shapes how the clinic handles maintenance patients, because the people asking these questions are not asking them abstractly.

Patients stay in private rooms with 24/7 medical care throughout treatment. Set-and-setting (meaning the patient’s mental state going in and the environment surrounding them during dosing) is treated as a clinical variable rather than as atmosphere, because both measurably shape the experience. The ibogaine itself is directly sourced from a laboratory in South Africa, and discounts are available for military veterans and first responders.

Patients coming off opiates should expect a gray day after treatment, a period of fatigue, residual withdrawal, and recovery that follows the main session. Medication is provided to ease those symptoms. Younger patients often move through it faster, while older patients sometimes experience a two-day gray day. Knowing this in advance is part of the preparation.

Aftercare and Boosters

Only one full ibogaine dose is considered safe within a three- to four-month period, which means the treatment cannot be repeated on demand. Patients get two booster doses, which are much smaller and work by raising noribogaine levels in the brain rather than reproducing the full session.

Aftercare includes therapy sessions, and this is the part that determines whether the rest of it holds. For patients with PTSD, ibogaine can help significantly, but it is not a cure, and therapy and integration afterward are required. For patients who came to reduce opioid tolerance or come off pain medication, outcomes vary. Some find their pain has resolved. Others are referred to a pain management specialist, and some need to resume medication temporarily.

A Different Definition of Long-Term

While maintenance medications focus on managing opioid dependence daily and ibogaine aims for its total discontinuation, the choice between them ultimately depends on which philosophy aligns with an individual’s unique medical situation and personal recovery goals.

Two Meanings of the Same Word

Both approaches describe themselves in terms of long-term outcomes, and they mean different things by it. Maintenance medications offer long-term stability and harm reduction, delivered daily, with a strong evidence base behind them. Ibogaine represents a different philosophy, centered on the possibility of discontinuing opioid dependence rather than managing it.

The Question That Actually Matters

The question worth asking is not which treatment is better in the abstract. It is which approach fits this person’s medical situation, their treatment goals, and the recovery plan they are actually going to follow. Those are different questions, and they produce different answers for different people.

Addiction Treatment at Experience Ibogaine

At Experience Ibogaine, we understand that managing opioid use disorder is not a matter of finding a single superior treatment, but rather selecting the approach that aligns with an individual’s specific medical needs and recovery goals. With our team of certified professionals, we will help assess whether ibogaine is the right path forward in your treatment journey or if maintenance would better suit your current health goals. Contact us today to schedule an appointment, so we can determine the best possible care plan for your addiction recovery needs.

Frequently Asked Questions (FAQs)

References

• Substance Abuse and Mental Health Services Administration. “Chapter 3D: Buprenorphine.” Substance Abuse and Mental Health Services Administration, 2021.
• Kumar, R. et al. “Buprenorphine.” StatPearls Publishing, January, 2024.
• Togioka, B. et al. “Buprenorphine and Naloxone.” StatPearls Publishing, February 24, 2024.
• National Institute on Drug Abuse. “Medications for Opioid Use Disorder.” National Institute on Drug Abuse, March, 2025.
• Health and Human Services Department. “Medications for the Treatment of Opioid Use Disorder.” U.S. Federal Register, February 2, 2024.
• Substance Abuse and Mental Health Services Administration. “Protracted Withdrawal.” Substance Abuse and Mental Health Services Administration, July, 2010.
• Frank, D. et al. “It’s Like Liquid Handcuffs: The Effects of Take-Home Dosing Policies on Methadone Maintenance Treatment Patients’ Lives.” Harm Reduction Journal, August 14, 2021.
• Esperanca, M. et al. “Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders, A Scoping Review.” Molecules, February 4, 2026.
• Sharma, P. et al. “From Monotherapy to Sequential Models: An Updated Scoping Review on Ibogaine’s Role in Treatment for Psychiatric Disorders.” Journal of Psychopharmacology, May 12, 2026.
• Mash, D. et al. “Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence.” Frontiers in Pharmacology, June 4, 2018.
• Noller, G. et al. “Ibogaine Treatment Outcomes for Opioid Dependence From a Twelve-Month Follow-Up Observational Study.” The American Journal of Drug and Alcohol Abuse, April 12, 2017.